Azathioprine-induced interstitial nephritis in an anti-neutrophil cytoplasmic antibody (ANCA) myeloperoxidase (MPO) vasculitis patient by Pires da Rosa, Gilberto et al.
DOI: 10.5152/eurjrheum.2017.17062
Azathioprine-induced interstitial nephritis in an 
anti-neutrophil cytoplasmic antibody (ANCA) 
myeloperoxidase (MPO) vasculitis patient
Introduction
Azathioprine (AZA) still corresponds to the mainstay maintenance therapy in anti-neutrophil cytoplasmic 
antibody (ANCA)-associated vasculitides (1, 2). This drug is mostly well-tolerated, but numerous side ef-
fects are recognized. These can be divided in two categories: dose-dependent toxic side effects and rarer 
dose-independent hypersensitivity reactions (1, 3). The time lag to symptoms in hypersensitivity reactions 
is wide, ranging from 1 week to 16 months after starting therapy, but occurs more frequently in the first 4 
weeks (1, 4). Resolution is swift upon drug cessation, with symptoms waning within a week (4). 
Renal impairment with biopsy-proven interstitial nephritis is a rare event that has been reported in patients 
with vasculitides (2). Prognosis is favorable with drug cessation, and rechallenge should be avoided be-
cause of the risk of a severe, even life-threatening, acute response within hours (1, 2).
Case Presentation 
A 50-year-old Caucasian man with kidney-limited ANCA MPO vasculitis was admitted to our emergency 
department due to malaise and fever. The diagnosis of vasculitis had been achieved 6 months earlier in 
context of rapidly progressive renal failure. Laboratory examination had revealed positivity for ANCA MPO, 
with renal biopsy displaying crescentic glomerulonephritis. Progressive recovery of renal function was 
attained under hemodialysis, plasmapheresis, and immunosuppression with methylprednisolone pulses 
and cyclophosphamide (Endoxan, Baxter Pharmaceuticals, NSW, Australia) administered according to the 
CYCLOPS protocol. After induction therapy, the patient no longer required renal function replacement ther-
apy, with a serum creatinine value stabilized at 2.54 mg/dL. Five weeks after the last cyclophosphamide 
pulse (cumulative dose 9 g), maintenance therapy was initiated with oral AZA (Imuran; Aspen Pharma 
Trading, Dublin, Ireland) 50 mg/day.
Thirteen days later, the patient was admitted to our emergency department complaining of general mal-
aise, fever, diaphoresis, and productive cough with mucous sputum for the last 24 hours. 
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Abstract
Azathioprine (AZA) is used in a wide array of autoimmune diseases, still corresponding to the main-
stay maintenance therapy in anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides. 
Although generally well-tolerated, several side effects are recognized. We report the case of a 50-year-
old Caucasian man with kidney-limited ANCA myeloperoxidase (MPO) vasculitis who presented with 
general malaise, fever, worsening renal function, and elevated inflammatory markers 2 weeks after 
the initiation of therapy with oral AZA. Although a disease relapse was suspected, renal biopsy re-
vealed an eosinophilic infiltrate, suggestive of acute interstitial nephritis. After suspension of AZA, a 
sustained improvement of renal function and normalization of inflammatory markers was observed. 
A diagnosis of allergic interstitial nephritis secondary to AZA was established, corresponding to the 
first biopsy-proven case described in an ANCA MPO vasculitis patient. Although rare, renal toxicity 
of AZA must be present in the clinician´s mind, avoiding the straightforward assumption of disease 
relapse in the case of worsening renal function.
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Physical examination on admission displayed 
a patient with good general status, feverish 
(auricular temperature of 40.4°C), with a blood 
pressure of 143/95 mmHg, heart frequency 
of 125 beats per minute, and peripheral oxy-
gen saturation measured by pulse oximetry of 
100%. 
Laboratory examination revealed normocyt-
ic/normochromic anemia (11.4 g/dL), white 
blood cells count of 9.44´109/L with predomi-
nant neutrophilia (92.2 %) and normal platelet 
count. Renal function was stable (serum creat-
inine 2.37 mg/dL, urea 85 mg/dL) but elevated 
C-reactive protein (CRP)-134.5 mg/L (normal<5 
mg/L) was detected. Urine analysis displayed 
leukocyturia and erythrocyturia. Renal ultra-
sonography exhibited normally dimensioned 
kidneys with preserved cortico-parenchymal 
differentiation and increased echogenicity. 
Chest computerized tomography scan re-
vealed no evident abnormalities. 
Considering the clinical picture of fever in an 
immunosuppressed patient, and pondering 
the possibility of a relapse of the vasculitic dis-
ease, the patient was hospitalized for further 
study. Antibiotherapy with piperacillin/tazo-
bactam was instituted. Ambulatory immuno-
suppressive therapy was maintained.
On admission, a new papular rash located on 
the dorsum of hands was found (Figure 1). 
Magnetic resonance imaging of the lumbar 
spine was performed revealing no signs of 
spondylodiscitis. The patient maintained fever 
spikes, with gradual worsening of renal func-
tion (to serum creatinine 3.43 mg/dL, urea 71 
mg/dL) with sustained CRP elevation and leu-
kocytosis at the fourth day of hospitalization 
and antibiotic, strengthening the hypothesis 
of a vasculitic relapse. Pulses of methylprednis-
olone were instituted (500 mg/day) and a re-
nal biopsy scheduled prior to a new induction 
cycle of cyclophosphamide, in order to further 
sustain the relapse hypothesis. A worsening 
of the dermatologic lesions of hands was also 
verified, with a purpuric appearance and scat-
tered pustules (Figure 2), and skin biopsy was 
performed. 
After the third methylprednisolone adminis-
tration, the patient maintained a progressively 
aggravated renal function (serum creatinine 
5.96 mg/dL, urea 175 mg/dL). Renal biopsy was 
performed, revealing an eosinophilic infiltrate 
suggestive of acute interstitial nephritis (aller-
gic type), and sequelae of vasculitis, with no 
signs of acute activity (Figure 3, 4). Despite the 
absence of peripheral eosinophilia and eosino-
philuria, the possibility of allergic interstitial ne-
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Figure 1. Papular rash located to the dorsum 
of hands at admission
Figure 2. Worsening of the dermatologic le-
sions, with a purpuric appearance and scat-
tered pustules. Biopsy revealed a neutrophilic 
dermatitis, with no evidence supporting the 
diagnosis of vasculitis
Figure 3. Renal biopsy pathology: marked 
intersticial inflammation with eosinophil-pre-
dominant infiltrate (hematoxylin and eosin 
400x)
Figure 4. Renal biopsy pathology: tubulitis 
with intraepithelial neutrophils found in the 
renal tubules (hematoxylin and eosin 400x)
Figure 5. Patient’s creatinine and CRP levels, and their evolution during hospitalization. Cortico-
steroids were introduced on the third day after admission and azathioprine stopped on the sixth 
day of hospitalization, with a concomitant improvement of renal function.
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phritis secondary to AZA was considered, lead-
ing to discontinuation of both this medication 
and antibiotic. Corticotherapy was adjusted to 
oral prednisolone 1 mg/kg/day (70 mg/day). A 
sustained improvement of renal function was 
verified with a parallel decrease in inflammato-
ry markers, with stabilized values at discharge 
(day 18 of hospitalization) at a serum creatinine 
value of 2.47 mg/dL and CRP of 2.3 mg/L (ana-
lytic evolution displayed in Figure 5). A diagno-
sis of allergic interstitial nephritis secondary to 
AZA was established.
Additionally, progressive healing of the cuta-
neous lesions was verified, with no residual 
scarring, and biopsy revealed a neutrophilic 
dermatitis, with no evidence supporting the 
diagnosis of vasculitis. Adding the history of 
fever, laboratorial abnormalities, and the histo-
logic findings on skin biopsy, a component of 
the Sweet Syndrome was assumed.
Considering the diagnosis of allergic interstitial 
nephritis secondary to AZA, maintenance ther-
apy with rituximab (MabThera, Roche Phar-
maceuticals, Basel, Switzerland) was instituted 
according to the MAINRITSAN trial scheme: 
two administrations (at a fixed 500-mg dose) 
separated by 2 weeks, and then at months 6, 
12, and 18 after the first infusion (5). The patient 
evolved favorably with stable renal function 
and clinical status on follow-up.
Discussion
Interstitial nephritis due to AZA sensitivity, 
though associated with various disorders, has 
only been confirmed through biopsy in 12 cas-
es: five cases of granulomatosis with polyangii-
tis (2, 3, 6-8); one of polyarteritis nodosa; two of 
Henoch-Schönlein purpura; one of Goodpas-
ture syndrome; one of chronic glomerulone-
phritis; and two transplant recipients (6, 9-11). 
In our patient, the diagnosis of hypersensitiv-
ity reaction was made more difficult by the 
similarity of the symptomatology with the 
presenting signs of the vasculitic disease, 
mimicking a disease relapse. In this scenario, 
the biopsy played an essential part directing 
the diagnosis. The role of repeat biopsy is not 
formally stipulated for ANCA vasculitides, and 
a more standardized approach could prove 
beneficial.
In our case, the renal biopsy displayed an eo-
sinophilic infiltrate suggestive of acute intersti-
tial nephritis, compatible with hypersensitivity 
reaction to AZA, in which polymorphonuclear 
infiltrate constitutes the most reported histo-
logical feature, but with one case of eosino-
phil-rich infiltrate being also stated (2). More-
over, the absence of acute signs of disease 
activity in the biopsy weakened the relapse 
hypothesis, and the time lag to symptoms af-
ter drug initiation and the prompt resolution 
after cessation reinforced the diagnosis of 
hypersensitivity reaction to AZA. The absence 
of eosinophilia and eosinophiluria could be 
seen as a limitation, but urinary eosinophils 
are currently considered a test with poor sen-
sitivity and low positive predictive value, with 
its absence not excluding at all the diagnosis, 
and eosinophilia is present in only 25%-50% 
of acute interstitial nephritis cases (12). A list of 
renal diseases associated with eosinophilia is 
available in Table 1. A plausible alternate diag-
nosis considering the biopsy findings could be 
eosinophilic granulomatosis with polyangiitis 
(EGPA). Nevertheless, while the prevailing pic-
ture in EGPA is ANCA-associated necrotizing 
crescentic glomerulonephritis, in acute allergic 
drug-induced interstitial nephritis, the major 
histologic abnormalities are in the interstitium, 
which is expanded by a number of inflamma-
tory cells, with the presence of large numbers 
of eosinophils, as it is seen in this patient.
Sweet Syndrome, also denominated acute 
neutrophilic dermatosis, has been associat-
ed both with autoimmune diseases such as 
ANCA vasculitides, and drugs, namely AZA (1). 
In these cases, distinction between a disease 
and drug-induced Sweet Syndrome might be 
problematic. The patient fulfilled the diagnos-
tic criteria for Sweet Syndrome, including the 
two major criteria (abrupt onset of painful er-
ythematous plaques and histopathologic ev-
idence of a dense neutrophilic infiltrate with-
out evidence of leukocytoclastic vasculitis). 
Additionally, the patient fulfilled the criteria for 
drug-induced Sweet Syndrome, including the 
temporal relationship between drug ingestion 
and clinical presentation and the temporally 
related resolution of lesions after drug with-
drawal. An alternative diagnosis considering 
the type of skin lesions that the patient dis-
played could be neutrophilic urticarial derma-
tosis. The main factor strengthening the Sweet 
Syndrome hypothesis was the presence of 
dermal edema (both clinical and histological-
ly). Additionally, the neutrophilic infiltrate was 
denser than expected in the case of neutro-
philic urticaria. So, considering the presence 
of a drug-induced Sweet Syndrome compo-
nent in this patient, the possibility of the kid-
ney biopsy findings corresponding to a renal 
manifestation of this disease was raised. Nev-
ertheless, literature review revealed no cases 
of interstitial nephritis as renal manifestation in 
Sweet Syndrome (being only described mes-
angiocapillary glomerulonephritis), reinforcing 
the diagnosis of a hypersensitivity reaction to 
AZA.
This case report corresponds, according to our 
literature review, to the first account of a biop-
sy-proven allergic interstitial nephritis second-
ary to AZA in an ANCA MPO vasculitis patient, 
raising awareness to this entity, both for the 
potentially severe complications and the need 
for a therapy significantly distinct from disease 
relapse.
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